COMMERCIAL SUPPORTThe Arizona Society of Pathologists thanks the commercial supporters listed below for their valued support of our Fall 2021 Meeting, held on Saturday, November 13, 2021 as a hybrid meeting.
|
|
GOLD LEVEL COMMERCIAL SUPPORTERS
|
|
|
Caris Life Sciences® is a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).
www.CarisLifeSciences.com Kristina Lebeda - klogan@carisls.com |
APS leverages 60+ years of pathology and laboratory revenue cycle management experience to provide industry leading charge and data capture, coding and denial management processes. We utilize a proprietary platform, which allows us to mine data and deliver comprehensive reporting to offer meaningful insights into your practice and superior results.
www.apsmedbill.com. Gerrick Gonzales - gsgonzales@apsmedbill.com |
|
|
|
Blueprint Medicines is a global precision therapy company that aims to invent transformative medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy.
https://www.blueprintmedicines.com/about/ Michael Jones email : mjones2@blueprintmedicines.com |
At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.
www.merck.com Tony Frasso - tony.frasso@merck.com |
SILVER LEVEL COMMERCIAL SUPPORTERS
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
https://www.astrazeneca.com/ Jim Wynne - 714-222-6119 jim.wynne@astrazeneca.com |
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.
Beth Weidman, RN, MS, FNP Precision Medicine Consultant Eli Lilly and Company 217.246.5619 (mobile) weidman_beth@lilly.com | www.lilly.com |
|
Stemline Therapeutics
Kelsey Mgone kmgone@stemline.com |
Allakos is a clinical-stage biotechnology company developing therapeutic antibodies for inhibitory receptors on the surface of immune effector cells involved in allergic, inflammatory and proliferative diseases. Our lead drug candidate is an investigational monoclonal antibody designed to target Siglec-8, an inhibitory receptor selectively found on mast cells and eosinophils. Our most advanced clinical programs are in EGIDs, including eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD) and eosinophilic esophagitis (EoE).
The information in the links below is intended for U.S. Healthcare Professionals Only. Clicking on the resources below will take you away from the Arizona Society of Pathologists website. To learn more about eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD), please visit: http://divedeeper.com/. For Medical Information, please contact: Medinfo@allakos.com |